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PTH group. Microstructure of the trabecular and cortical 
bone in the PTH-IBN group was not significantly different 
from that in the PTH group. In histomorphometric analysis 
of the lumbar vertebra, eroded surface and osteoclast sur-
face in the PTH-Veh group were no different from those in 
the PTH group, whereas they were lower in the PTH-IBN 
group. Osteoid surface, osteoblast surface, and mineralize 
surface decreased in both PTH-IBN and PTH-Veh groups 
compared to the PTH group, and these parameters in the 
PTH-IBN group were lower than in the PTH-Veh group. 
These results indicated that intermittent IBN after PTH 
treatment suppressed bone turnover and maintained BMD, 
biomechanical strength, and microstructure in the lumbar 
spine and femur of OVX rats.
Keywords Bone biomechanical strength · Bone mineral 
density · Histomorphometry · Ibandronate · Parathyroid 
hormone
Introduction
Agents for the treatment of osteoporosis fall into two major 
classes: anti-bone-resorptive agents and anabolic agents. 
There are several types of anti-resorptive treatment, such as 
bisphosphonates, receptor activator of nuclear factor kappa-
B ligand inhibitors, selective estrogen receptor modulators, 
and vitamin D analogues. On the other hand, human para-
thyroid hormone (PTH)—either PTH(1–34) or full-length 
human PTH(1–84)—is the only anabolic agent currently 
approved for treatment of osteoporosis [1].
PTH increases osteoblast numbers and bone formation 
via stimulation of osteoblastogenesis and inhibition of 
osteoblast apoptosis [2]. In postmenopausal women with 
prevalent vertebral fractures, PTH is reported to increase 
Abstract Although parathyroid hormone (PTH) 
expresses an anabolic effect on bone mass, the increased 
bone mass disappears once PTH treatment is withdrawn. 
Therefore, sequential treatment with anti-bone-resorptive 
agents is required to maintain bone mass after PTH treat-
ment. We examined the effect of sequential treatment 
with ibandronate (IBN), a nitrogen-containing bisphos-
phonate, following PTH in ovariectomized (OVX) rats. 
Wistar-Imamichi rats (27 weeks old) were ovariectomized 
and treated with PTH (10 µg/kg, s.c.; 5 times/week; PTH 
group) for 8 weeks from 8 weeks after OVX. Thereaf-
ter, PTH was withdrawn and rats were administered IBN 
(10  µg/kg, s.c.; every 4 weeks; PTH-IBN group) or vehi-
cle (PTH-Veh group) for another 8 weeks. PTH increased 
bone mineral density (BMD) measured by dual-energy 
X-ray absorptiometry and biomechanical strength in the 
lumbar spine and femur as compared to the disease con-
trol rats. BMD and biomechanical strength in the PTH-Veh 
group were lower than in the PTH group, whereas in the 
PTH-IBN group they were maintained at the level of the 
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bone mineral density (BMD) of the spine and reduce the 
risk of vertebral fractures [3]. Favorable effects of PTH on 
BMD and fracture risk are also reported in men with osteo-
porosis [4]. Owing to its high potential to increase BMD 
and reduce fracture risk, PTH is used for the treatment of 
osteoporosis patients that have a high risk of fracture. PTH 
also improves the microstructure of trabecular bone and the 
collagen cross-link ratio in bone [5, 6]. However, because 
carcinogenicity studies in rats have found that PTH induces 
osteosarcomas, the use of PTH is limited to no more than 2 
years [7].
Although PTH treatment increases lumbar spinal BMD, 
the increased BMD declines after PTH is withdrawn [8, 9]. 
Therefore, administration of anti-bone-resorptive agents is 
recommended after discontinuation of PTH treatment [4, 
10–12]. Ibandronate (IBN), a nitrogen-containing bispho-
sphonate, is widely used in the treatment of osteoporosis. 
It can be administered at extended dosing intervals in both 
intravenous and oral formulations [13, 14]. Monthly intra-
venous administration of IBN significantly increased BMD 
with a reduction in bone turnover markers and reduced the 
incidence of vertebral fractures in patients with primary 
osteoporosis [14]. Concurrent and sequential therapies of 
PTH(1–84) with IBN similarly increased the BMD of the 
lumbar spine and hip over 2 years [15]. However, how IBN 
affects bone after PTH treatment are not yet clear. In the 
current study, we examined the effect of sequential treat-
ment with IBN following PTH in ovariectomized rats.
Materials and Methods
Experimental Design
Twenty-five-week-old female Wistar-Imamichi rats were 
purchased from the Institute for Animal Reproduction (Iba-
raki, Japan) and were acclimatized for 2 weeks under stand-
ard laboratory conditions at 20–26 °C, 30–70% humidity, 
and a 12 h:12 h light/dark cycle. All animals had free access 
to tap water and standard commercial rodent chow (CE-2; 
CLEA Japan, Inc., Tokyo, Japan). Animals were ovariecto-
mized (OVX) or sham-operated (Sham) at 27 weeks of age, 
and were left untreated for 8 weeks. Rats were then rand-
omized according to their BMD and body weight into seven 
groups (Fig. 1). Three of the OVX groups received subcu-
taneous injections of human PTH(1–34) (10 µg/kg per day, 
five times per week; Peptide Institute, Inc., Osaka, Japan), 
and the remaining OVX groups and Sham groups received 
subcutaneous injections of vehicle (phosphate–citrate-buff-
ered solution consisting of 16.7  mM disodium hydrogen-
phosphate, 8.4 mM citric acid, 100 mM sodium chloride, 
and 0.05% Tween-80; pH 5.0; 1 mL/kg per day) [16]. After 
8 weeks of treatment, rats in three groups (Sham, OVX/
Vehicle, and OVX/PTH) were euthanized, and treatment 
in the remaining groups was continued for an additional 8 
weeks: PTH-treated groups were switched to subcutaneous 
injections of IBN (10 µg/kg, once every 4 weeks; Chugai 
Pharmaceutical Co., Ltd., Tokyo, Japan) or vehicle (saline), 
and vehicle-treated OVX and Sham groups continued to 
receive vehicle. The dosages of PTH and IBN were deter-
mined by reference to previous reports as doses sufficient 
to increase BMD and bone biomechanical strength in OVX 
rats [17, 18]. Tetracycline (20  mg/kg) and calcein (6  mg/
kg) were injected subcutaneously for bone labeling at 8 and 
3 days, respectively, prior to necropsy.
Blood and urine were collected every 4 weeks. Blood 
was collected from the jugular vein under isoflurane anes-
thesia and centrifuged to obtain serum. Urine was collected 
using individual metabolic cages. Serum and urine were 
stored at −40 °C until biochemical analysis.
At the end of the treatment, animals were euthanized 
by exsanguination from the abdominal aorta under iso-
flurane anesthesia. The lumbar spine and bilateral femurs 
were excised. The second through fourth lumbar vertebrae 
(L2–L4) and the right femur were retained in 70% etha-
nol. The fifth lumbar vertebra (L5) and the left femur were 
wrapped in saline-soaked gauze and stored at −30 °C prior 
to biomechanical testing. This study was performed accord-
ing to the experimental protocol approved by the Institu-
tional Animal Care and Use Committee at Chugai Pharma-
ceutical Co., Ltd.
Measurement of BMD
For measurement of BMD for grouping of animals, ani-
mals were anesthetized using isoflurane, and the BMD 
of L2–L5 was measured in  vivo by dual-energy X-ray 
OVX
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Fig. 1  Experimental design. Eight weeks after ovariectomy (OVX), 
rats were treated with PTH(1–34) (10  µg/kg, s.c., five times/week) 
or vehicle for 8 weeks. Thereafter, PTH treatment was withdrawn 
and the PTH-treated rats were administered ibandronate for another 
8 weeks (10 µg/kg, s.c., every 4 weeks; IBN) or vehicle. Bone min-
eral density (BMD) and biomechanical properties were measured, 
and bone histomorphometry was performed at 8 and 16 weeks. Bone 
turnover markers were measured every 4 weeks. n = 10 for each group
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absorptiometry with a DCS-600EX bone densitom-
eter (pixel size: 1 mm × 0.5 mm, Aloka Co., Ltd., Tokyo, 
Japan). For measurement of the BMD in excised bone sam-
ples, the BMD of the lumbar spine (L2–L4) and of the right 
femur was determined using a DCS-600EX bone densitom-
eter. For data analysis, the femur was divided into ten equal 
segments along its major axis and BMD was calculated in 
3 parts: proximal femur (the mean BMD of the 3 proximal 
segments), middle femur (the mean BMD of the 4 middle 
segments), and distal femur (the mean BMD of the 3 distal 
segments).
Biomechanical Testing
Biomechanical strength was performed with a mechanical 
testing machine (TK-252C; Muromachi Kikai Co., Ltd., 
Tokyo, Japan). For the femur 3-point bending test, the 
upper loading device was aligned at the expected break-
ing point of the femoral shaft on the anterior side. The span 
between the two lower supports was set at 15 mm. The load 
was applied at a rate of 20 mm/min. Prior to the compres-
sion test of the L5 vertebral body, the vertebral arch and 
end plates were cut off with a diamond saw to obtain a 
specimen with planoparallel ends. The loading rate of the 
compression test was set at 2.5  mm/min. Maximum load 
and work to failure were determined from the load–dis-
placement curve, and ultimate stress and toughness were 
calculated [19]. Stiffness was determined from the slope 
of the linear elastic region of the load–displacement curve, 
and Young’s modulus was calculated. Moment of inertia 
of the femoral shaft was measured at the expected break-
ing point by peripheral quantitative computed tomography 
(pQCT; XCT Research M; Stratec Medizintechnik, Pforz-
heim, Germany) using Cortmode 1. Cross-sectional area at 
the mid-section of the L5 vertebra was quantified by pQCT 
using Contmode 2 and Peelmode 20.
Bone Histomorphometry
Bone histomorphometry was performed on the L3 verte-
bra and femoral diaphysis. Specimens were fixed in 70% 
ethanol and stained with Villanueva bone stain. After dehy-
dration, the specimens were embedded in methyl meth-
acrylate. Five-micrometer-thick sections of the L3 verte-
bral body were prepared to evaluate trabecular bone. For 
the femoral diaphysis, 20- to 30-µm-thick cross-cut ground 
sections were obtained for evaluation of cortical bone. 
Measurements of static and dynamic parameters were col-
lected with an image analyzing system (WinROOF 2013; 
Mitani Corp., Tokyo, Japan). The secondary spongiosa 
(approximately 4.416 mm2) located 0.5 mm away from the 
growth plate and 0.15  mm from the margin of the dorsal 
cortical shell of the L3 vertebral body was used to assess 
trabecular bone. The following variables were measured: 
bone volume (BV/TV, %), trabecular thickness (Tb.Th, 
µm), trabecular number (Tb.N, /mm), trabecular separation 
(Tb.Sp, µm), eroded surface (ES/BS, %), osteoclast surface 
(Oc.S/BS, %), osteoid surface (OS/BS, %), osteoblast sur-
face (Ob.S/BS, %), mineralized surface (MS/BS, %), min-
eral apposition rate (MAR, µm/day), bone formation rate 
(BFR/BS, µm3/µm2/year), tissue area (T.Ar,  mm2), marrow 
area (Ma.Ar,  mm2), cortical area (Ct.Ar,  mm2), cortical 
width (Ct.Wi, mm), endocortical perimeter (Ec.Pm, mm), 
and periosteal perimeter (Ps.Pm, mm). Nomenclature and 
units used in this study follow the report of the American 
Society for Bone and Mineral Research Histomorphometry 
Nomenclature Committee [20].
Biochemical Analysis
Urinary deoxypyridinoline (DPD) was measured using 
an Osteolinks-DPD kit (DS Pharma Biomedical, Osaka, 
Japan) and the data were corrected for urinary creatinine 
(Cr) concentration. Cr was measured with an autoanalyzer 
(TBA-120FR; Toshiba Medical Systems Co., Tochigi, 
Japan). Serum osteocalcin (OCN) was measured using an 
Osteocalcin Rat ELISA System (GE Healthcare Japan Co., 
Tokyo, Japan).
Statistical Analysis
All data are presented as the mean ± SEM. The differences 
between the groups were analyzed with one-way analysis 
of variance (ANOVA). Statistical differences between indi-
vidual groups were evaluated with Tukey’s multiple com-
parison test or Dunnett’s multiple comparison test. Statisti-
cal comparisons between the Sham group and the Vehicle 
or Veh-Veh groups, and between the Vehicle group and the 
PTH group were performed by unpaired t test. For all tests, 
P < 0.05 was considered statistically significant. Bonferroni 
correction was applied for analysis of bone turnover mark-
ers. Statistical analysis was carried out using JMP (SAS 
Institute Inc., Cary, NC, USA).
Results
BMD
OVX induced a significant reduction in the BMD of the 
lumbar spine and the femur compared to that in the Sham 
group (Fig.  2a–e). BMD in the PTH group was signifi-
cantly higher than in the Vehicle group at 8 weeks. At 16 
weeks, the BMD of the lumbar spine and the femur in the 
PTH-IBN and PTH-Veh groups was significantly higher 
than in the Veh-Veh group, and the BMD in the PTH-IBN 
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group was significantly higher than in the PTH-Veh group. 
The BMD of the lumbar spine and the proximal, distal, and 
whole femur in the PTH-Veh group was significantly lower 
than in the PTH group, whereas the BMD in the PTH-IBN 
group was not significantly different from that in the PTH 
group (Fig. 2a–c, e). The BMD of the middle femur in the 
PTH-IBN group was significantly higher than in the PTH 
group (Fig. 2d).
Bone Biomechanical Strength
In the compression test of the L5 vertebral body, OVX 
resulted in significant decreases in maximum load, ulti-
mate stress, and toughness compared to the Sham group at 
8 weeks (Fig. 3a; Table 1). In the PTH group, the values of 
all biomechanical parameters of the L5 vertebral body were 
higher than in the Vehicle group (Fig. 3a–c; Table 1). At 16 
weeks, maximum load, work to failure, ultimate stress, and 
toughness in the PTH-IBN group were significantly higher 
than in the Veh-Veh group, and all biomechanical strength 
parameters of the L5 vertebral body were significantly 
higher in the PTH-IBN group than in the PTH-Veh group 
(Fig.  3a–c; Table  1). In the PTH-Veh group, all biome-
chanical strength parameters were significantly lower than 
in the PTH group, whereas these parameters in the PTH-
IBN group were not significantly different from those in the 
PTH group.
In the 3-point bending test of the femoral shaft, PTH 
treatment resulted in higher maximum load, stiffness, and 
work to failure than was observed in the Vehicle group at 
8 weeks (Fig. 3d–f). OVX induced significant decreases in 
maximum load, stiffness, and ultimate stress of the femoral 
shaft in the Veh-Veh group compared to the Sham group 
at 16 weeks (Fig. 3d, e: Table 1). In the PTH-IBN group, 
maximum load, stiffness, work to failure, and ultimate 
stress of the femoral shaft were significantly higher than 
in the Veh-Veh group, and maximum load, work to failure, 
ultimate stress, and toughness were significantly higher 
than in the PTH-Veh group (Fig. 3d–f; Table 1). Maximum 
load, work to failure, ultimate stress, and toughness in the 
PTH-Veh group were significantly lower than in the PTH 
group, whereas in the PTH-IBN group these parameters 
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Fig. 2  Bone mineral density of the lumbar spine and femur. PTH(1–
34) (10 µg/kg, s.c., five times/week) or vehicle was administered to 
ovariectomized (OVX) rats for 8 weeks from 8 weeks after OVX 
surgery. Ibandronate (10  µg/kg, s.c., every 4 weeks; IBN) or vehi-
cle was administered sequentially for another 8 weeks following 
PTH treatment. a lumbar spine, b whole femur, c proximal femur, 
d middle femur, e distal femur. Data are presented as mean + SEM. 
(n = 10 for each group). a P < 0.05 versus Sham by unpaired t test. b 
P < 0.05 versus Vehicle by unpaired t test. c P < 0.05 versus Veh-Veh; 
d P < 0.05 versus PTH-IBN by Tukey’s multiple comparison test. e 
P < 0.05 PTH versus PTH-IBN or PTH-Veh by Dunnett’s multiple 
comparison test
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Fig. 3  Biomechanical strength of the L5 vertebral body and the fem-
oral shaft. PTH(1–34) (10 µg/kg, s.c., five times/week) or vehicle was 
administered to ovariectomized (OVX) rats for 8 weeks from 8 weeks 
after OVX surgery. Ibandronate (10 µg/kg, s.c., every 4 weeks; IBN) 
or vehicle was administered sequentially for another 8 weeks follow-
ing PTH treatment. Maximum load, stiffness, and work to failure for 
the L5 vertebral body (a, b, c) and the femoral shaft (d, e, f) were 
determined by compression test and 3-point bending test, respec-
tively. Data are presented as mean + SEM. (n = 10 for each group). 
a P < 0.05 versus Sham by unpaired t test. b P < 0.05 versus Vehicle 
by unpaired t test. c P < 0.05 versus Veh-Veh; d P < 0.05 versus PTH-
IBN by Tukey’s multiple comparison test. e P < 0.05 PTH versus 
PTH-IBN or PTH-Veh by Dunnett’s multiple comparison test
Table 1  Material biomechanical properties of L5 the vertebral body and femoral shaft
Mean ± SEM (n = 10 for each group)
a P < 0.05 versus Sham by unpaired t test
b P < 0.05 versus Vehicle by unpaired t test
c P < 0.05 versus Veh-Veh;
d P < 0.05 versus PTH-IBN by Tukey’s multiple comparison test
e P < 0.05 PTH versus PTH-IBN or PTH-Veh by Dunnett’s multiple comparison test
Veh vehicle, IBN ibandronate
8 weeks 16 weeks
Sham OVX Sham OVX
Vehicle PTH Veh-Veh PTH-IBN PTH-Veh
L5 vertebral body
 Ultimate stress (MPa) 40.9 ± 1.2 34.4 ± 1.9a 47.5 ± 2.2b 38.8 ± 1.5 34.4 ± 1.8 48.3 ± 2.3c 32.6 ± 2.4d, e
 Young’s modulus (MPa) 759.2 ± 48.4 646.1 ± 52.5 845.6 ± 71.3b 660.8 ± 63.0 783.8 ± 42.5 881.6 ± 26.0 613.4 ± 55.0c,d,e
 Toughness (MPa) 1.55 ± 0.10 1.27 ± 0.08a 1.79 ± 0.10b 1.95 ± 0.24 1.07 ± 0.06a 1.90 ± 0.10c 1.38 ± 0.12d,e
Femoral shaft
 Ultimate stress (MPa) 164.9 ± 6.2 164.3 ± 4.1 171.6 ± 3.3 166.4 ± 4.2 153.1 ± 3.3a 171.5 ± 2.9c 154.7 ± 2.4d,e
 Young’s modulus (MPa) 4286.7 ± 140.9 4143.8 ± 139.2 4523.9 ± 201.8 4553.1 ± 151.7 4242.4 ± 177.3 4700.9 ± 228.1 4348.8 ± 141.8
 Toughness (MPa) 6.27 ± 0.35 6.46 ± 0.31 7.21 ± 0.20 6.23 ± 0.27 6.14 ± 0.17 6.85 ± 0.30 5.87 ± 0.29d,e
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Bone Histomorphometry
OVX induced a significant reduction in BV/TV in the tra-
becular bone of the L3 vertebra, accompanied by significant 
decreases in Tb.Th and Tb.N, and a significant increase in 
Tb.Sp compared to the Sham group at 8 weeks (Table 2). 
PTH resulted in higher BV/TV and Tb.Th and lower Tb.Sp 
compared to the Vehicle group. In the PTH-IBN and PTH-
Veh groups, BV/TV and Tb.N were significantly higher 
than in the Veh-Veh group, and Tb.Sp was significantly 
lower than in the Veh-Veh group. Tb.Th was significantly 
higher in the PTH-IBN group than in the Veh-Veh group. 
BV/TV and Tb.Th were significantly higher in the PTH-
IBN group than in the PTH-Veh group. BV/TV and Tb.Th 
in the PTH-Veh group were significantly lower than in the 
PTH group, whereas in the PTH-IBN group they were not 
significantly different from those in the PTH group.
OVX showed a tendency to increase bone resorp-
tion parameters (ES/BS and Oc.S/BS) and significantly 
increased bone formation parameters (OS/BS, Ob.S/BS, 
MS/BS, and BFR/BS) in the L3 vertebra at 8 weeks as 
compared to the Sham group (Table 2). PTH did not affect 
bone resorption parameters but significantly increased bone 
formation parameters compared to the Vehicle group. Bone 
resorption parameters in the PTH-IBN group were sig-
nificantly lower than in the Veh-Veh group or PTH group, 
whereas in the PTH-Veh group they did not change com-
pared to the Veh-Veh group or PTH group. OS/BS, Ob.S/
BS, and MS/BS in the PTH-IBN group were significantly 
lower than in the Veh-Veh group or PTH group. Bone for-
mation parameters in the PTH-Veh group were not sig-
nificantly different from those in the Veh-Veh group, but 
they were significantly lower than in the PTH group. OS/
BS, Ob.S/BS, and MS/BS in the PTH-IBN group were 
significantly lower than in the PTH-Veh group. MAR and 
BFR/BS in the PTH-IBN group were not able to be deter-
mined because double fluorescence bone labeling was not 
observed.
In the cortical bone of the femoral diaphysis, OVX 
significantly increased T.Ar, Ma.Ar, and Ec.Pm, and sig-
nificantly decreased Ct.Wi compared to the Sham group 
at 8 weeks (Table 3). PTH treatment showed significantly 
higher Ct.Ar and Ct.Wi, and lower Ma.Ar and Ec.Pm com-
pared to the Vehicle group. OVX and PTH treatment did 
not change Ps.Pm. In the PTH-IBN group, Ct.Ar and Ct.Wi 
were significantly higher than in the Veh-Veh group or 
PTH-Veh group, and Ma.Ar and Ec.Pm were significantly 
lower than in the Veh-Veh group or PTH-Veh group. In the 
PTH-Veh group, Ct.Wi was significantly higher than in the 
Veh-Veh group, and Ma.Ar, Ct.Ar, and Ec.Pm were not 
significantly different from those in the Veh-Veh group. In 
the PTH-Veh group, Ma.Ar and Ec.Pm were significantly 
Table 2  Histomorphometry of the trabecular bone of the L3 vertebra
Mean ± SEM (n = 10 for each group)
a P < 0.05 versus Sham by unpaired t- t est
b P < 0.05 versus Vehicle by unpaired t test
c P < 0.05 versus Veh-Veh;
d P < 0.05 versus PTH-IBN by Tukey’s multiple comparison test
e P < 0.05 PTH versus PTH-IBN or PTH-Veh by Dunnett’s multiple comparison test
f P < 0.05 versus PTH by unpaired t test
Veh vehicle, IBN ibandronate, ND not detected
8 weeks 16 weeks
Sham OVX Sham OVX
Vehicle PTH Veh-Veh PTH-IBN PTH-Veh
BV/TV (%) 31.9 ± 1.5 22.9 ± 1.1a 32.5 ± 1.4b 31.0 ± 1.2 20.1 ± 1.3a 35.4 ± 1.7c 26.4 ± 1.5c,d,e
Tb.Th (μm) 87.0 ± 3.6 76.4 ± 2.9a 104.5 ± 4.4b 82.9 ± 2.2 74.6 ± 3.6 108.9 ± 4.8c 85.3 ± 4.0 d,e
Tb.N (/mm) 3.67 ± 0.10 2.99 ± 0.08a 3.12 ± 0.09 3.74 ± 0.10 2.67 ± 0.08a 3.25 ± 0.08c 3.09 ± 0.09c
Tb.Sp (μm) 187.1 ± 7.8 260.2 ± 9.4a 218.1 ± 9.0b 186.5 ± 7.8 302.2 ± 13.1a 200.7 ± 9.0c 240.8 ± 10.9c,d
ES/BS (%) 8.41 ± 0.72 10.49 ± 1.09 11.35 ± 0.78 6.89 ± 0.44 10.04 ± 0.91a 6.41 ± 0.40c,e 10.45 ± 0.78d
Oc.S/BS (%) 1.51 ± 0.17 2.34 ± 0.38 2.54 ± 0.34 1.72 ± 0.15 2.44 ± 0.29a 1.30 ± 0.09c,e 2.36 ± 0.24d
OS/BS (%) 2.03 ± 0.35 11.10 ± 1.30a 16.70 ± 1.38b 3.13 ± 0.65 14.64 ± 1.98a 0.10 ± 0.05c,e 13.21 ± 1.14d,e
Ob.S/BS (%) 0.88 ± 0.17 4.75 ± 0.67a 8.53 ± 1.10b 1.40 ± 0.26 5.37 ± 0.97a 0.03 ± 0.02c,e 4.62 ± 0.74d,e
MS/BS (%) 4.11 ± 0.45 11.66 ± 1.21a 22.02 ± 1.19b 5.18 ± 0.70 13.19 ± 0.98a 2.12 ± 0.21c,e 14.43 ± 0.92d,e
MAR (μm/day) 1.15 ± 0.05 1.15 ± 0.04 1.43 ± 0.02b 1.31 ± 0.04 1.30 ± 0.05 ND 1.33 ± 0.03f
BFR/BS (μm3/μm2/year) 17.2 ± 2.0 48.9 ± 5.3a 115.5 ± 7.3b 24.5 ± 3.3 63.4 ± 6.2a ND 70.5 ± 5.8f
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higher than in the PTH group, and Ct.Ar and Ct.Wi were 
significantly lower, whereas these structural parameters in 
the PTH-IBN group were not significantly different from 
those in the PTH group.
PTH significantly decreased ES/BS and Oc.S/BS, and 
increased OS/BS and MS/BS in the endocortical femoral 
diaphysis (Table 3). In the PTH-IBN group, ES/BS, Oc.S/
BS, OS/BS, and MS/BS in the endocortical femoral dia-
physis were significantly lower than in the Veh-Veh group. 
In the PTH-Veh group, endocortical ES/BS and Oc.S/BS 
were not significantly different from those in the Veh-Veh 
group, and endocortical OS/BS and MS/BS were signifi-
cantly lower than in the Veh-Veh group. Endocortical ES/
BS and Oc.S/BS in the PTH-Veh group were significantly 
higher than in the PTH group, whereas in the PTH-IBN 
group they were not significantly different from those in the 
PTH group.
Bone Turnover Markers
Serum OCN in the Veh-Veh group was significantly higher 
than that in the Sham group through the study period 
(Fig.  4a). PTH treatment significantly increased OCN at 
4 weeks compared to the Veh-Veh group, and then OCN 
returned to the level of the Veh-Veh group at 8 weeks. 
Switching to IBN from PTH significantly decreased OCN 
compared to the Veh-Veh group, whereas switching to 
vehicle maintained OCN at the level of the Veh-Veh group.
Urinary DPD/Cr was significantly higher in the Veh-Veh 
group than in the Sham group (Fig.  4b). PTH treatment 
tended to increase DPD/Cr at 4 weeks, but not significantly. 
Switching to IBN significantly lowered DPD/Cr compared 
to the Veh-Veh group, whereas switching to vehicle did not 
change DPD/Cr.
Discussion
The increase in BMD induced by PTH is rapidly lost after 
withdrawal of PTH [8–10]. It was reported that the gains in 
spinal areal BMD as well as spinal volumetric BMD were 
significantly lost at 12 months after completing 12-month 
therapy with PTH in postmenopausal osteoporotic women 
[9]. It was also reported that spinal BMD and biomechani-
cal strength declined to the baseline levels at 8 weeks after 
withdrawal of PTH following 8-week treatment with PTH 
in OVX rats [21]. In the present study, PTH increased 
the BMD of the lumbar spine and the femur, and discon-
tinuation of PTH decreased that increased BMD. We also 
Table 3  Histomorphometry of the cortical bone of the femoral diaphysis
Mean ± SEM (n = 10 for each group)
a P < 0.05 versus Sham by unpaired t test
b P < 0.05 versus Vehicle by unpaired t test
c P < 0.05 versus Veh-Veh;
d P < 0.05 versus PTH-IBN by Tukey’s multiple comparison test
e P < 0.05 PTH versus PTH-IBN or PTH-Veh by Dunnett’s multiple comparison test
Veh vehicle, IBN ibandronate
8 weeks 16 weeks
Sham OVX Sham OVX
Vehicle PTH Veh-Veh PTH-IBN PTH-Veh
T.Ar  (mm2) 9.82 ± 0.13 10.20 ± 0.12a 10.32 ± 0.16 10.13 ± 0.18 10.26 ± 0.20 10.21 ± 0.18 10.39 ± 0.15
Ma.Ar  (mm2) 3.77 ± 0.09 4.32 ± 0.08a 3.90 ± 0.08b 3.99 ± 0.11 4.50 ± 0.10a 3.68 ± 0.09c 4.36 ± 0.13d,e
Ct.Ar  (mm2) 6.06 ± 0.06 5.88 ± 0.09 6.42 ± 0.11b 6.14 ± 0.08 5.76 ± 0.12a 6.53 ± 0.11c 6.03 ± 0.09d,e
Ct.Wi (mm) 0.64 ± 0.01 0.60 ± 0.01a 0.67 ± 0.01b 0.64 ± 0.01 0.58 ± 0.01a 0.69 ± 0.01c 0.61 ± 0.01c,d,e
Endocortical
 Ec.Pm (mm) 7.34 ± 0.09 7.78 ± 0.08a 7.38 ± 0.07b 7.52 ± 0.11 8.03 ± 0.11a 7.17 ± 0.11c 7.88 ± 0.10d,e
 ES/BS (%) 23.50 ± 1.25 29.30 ± 1.49a 14.25 ± 1.96b 16.85 ± 1.74 31.76 ± 2.02a 14.81 ± 2.86c 37.51 ± 1.64d,e
 Oc.S/BS (%) 4.36 ± 0.41 4.51 ± 0.43 1.73 ± 0.37b 2.35 ± 0.34 5.12 ± 0.70a 2.25 ± 0.68c 5.53 ± 0.74d,e
 OS/BS (%) 2.06 ± 0.74 9.80 ± 1.64a 16.59 ± 1.95b 2.12 ± 0.95 15.65 ± 2.27a 0.00 ± 0.00c,e 6.77 ± 0.96c,d,e
 MS/BS (%) 3.67 ± 0.81 8.46 ± 1.30a 26.59 ± 3.37b 4.59 ± 0.70 13.68 ± 1.89a 2.93 ± 0.61c,e 7.28 ± 0.92c,e
Periosteal
 Ps.Pm (mm) 11.55 ± 0.09 11.77 ± 0.08 11.82 ± 0.08 11.73 ± 0.10 11.76 ± 0.14 11.75 ± 0.12 11.85 ± 0.07
 MS/BS (%) 35.96 ± 3.27 50.93 ± 3.85a 50.06 ± 2.11 31.36 ± 5.99 44.30 ± 2.72 40.46 ± 1.68e 41.71 ± 1.94e
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observed a reduction in the biomechanical strength of the 
lumbar vertebra and femoral shaft after PTH withdrawal.
Bone microstructure as well as BMD contributes to 
bone biomechanical strength. Shahnazari et  al. reported 
that 4-month withdrawal following 4-month treatment with 
PTH decreased the increased BV/TV and Tb.Th in the lum-
bar vertebrae and the increased cortical thickness in the 
femur in OVX rats [22]. In this study, 8-week discontinu-
ation of PTH decreased BV/TV, which was increased by 
PTH, accompanied by a reduction in Tb.Th in trabecular 
bone of the L3 lumbar vertebra, and also decreased Ct.Ar 
and Ct.Wi, which were increased by PTH, accompanied by 
increased Ma.Ar in the cortical bone of the femoral shaft. 
This deterioration of trabecular and cortical architecture 
and the decrease in BMD resulted in a reduction in bone 
biomechanical strength after PTH withdrawal. The bone 
formation that is elevated by PTH treatment also decreases 
after discontinuation of PTH [9, 23]. In this study, histo-
morphometric analysis of the trabecular bone demon-
strated that bone formation, which was increased by PTH, 
decreased after PTH withdrawal as indicated by significant 
decreases in OS/BS, Ob.S/BS, MS/BS, MAR, and BFR/BS 
in the PTH-Veh group as compared to in the PTH group.
To maintain the BMD and bone biomechanical strength 
increased by PTH, sequential therapy after PTH with-
drawal is required. In this study, IBN was administered 
sequentially after PTH treatment in OVX rats. The BMD 
of the lumbar spine and the femur was lower in the PTH-
Veh group than in the PTH group, whereas the BMD in the 
PTH-IBN group was not significantly different from that in 
the PTH group and was higher than in the PTH-Veh group. 
These results indicated that switching to IBN from PTH 
maintained the BMD increased by PTH at the level it was 
before switching. Switching to IBN also maintained the 
biomechanical strength of the lumbar vertebrae at the level 
before switching. The values of the biomechanical param-
eters in the PTH-IBN group were greater than those in the 
PTH-Veh group, indicating that sequential treatment with 
IBN after PTH is effective with respect to the biomechani-
cal strength of the lumbar vertebrae.
In terms of histomorphometry, switching to IBN main-
tained BV/TV at the level it was before switching, accom-
panied with maintained Tb.Th. IBN also prevented the 
OVX-induced decrease in Tb.N, although PTH did not alter 
Tb.N. IBN resulted in a decrease in bone turnover after 
PTH treatment as shown by the decreases in both the bone 
resorption and bone formation parameters in the PTH-
IBN group. These results suggested that switching to IBN 
decreases bone turnover and preserved the microstructure 
of the trabecular bone, which could contribute to main-
taining the biomechanical strength of the lumbar vertebrae 
after withdrawal of PTH.
PTH improved the biomechanical strength of the femo-
ral shaft. Maximum load and work to failure of the femoral 
shaft were lower in the PTH-Veh group than in the PTH 
group, whereas these parameters in the PTH-IBN group 
showed no significant difference compared to the PTH 
group and were higher than in PTH-Veh group indicat-
ing that IBN maintained the biomechanical strength of the 
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Fig. 4  Time course of bone turnover markers. PTH(1–34) (10 µg/kg, 
s.c., five times/week) or vehicle was administered to ovariectomized 
(OVX) rats for 8 weeks from 8 weeks after OVX surgery. Ibandronate 
(10  µg/kg, s.c., every 4 weeks; IBN) or vehicle was administered 
sequentially for another 8 weeks following PTH treatment. Serum 
osteocalcin (a OCN) and urinary deoxypyridinoline normalized to 
urinary creatinine (b DPD/Cr) were measured every 4 weeks. Data 
are presented as mean ± SEM (n = 10 for each group). a P < 0.05 ver-
sus Sham by unpaired t test. b P < 0.05 versus Veh-Veh; c P < 0.05 
versus PTH-IBN by Tukey’s multiple comparison test among OVX 
groups followed by Bonferroni correction
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analysis of the femoral diaphysis revealed that PTH 
increased cortical bone accretion at the endocortical surface 
as shown by the increases in Ct.Ar, Ct.Wi, and endocortical 
MS/BS and the decreases in Ma.Ar and Ec.Pm. Switching 
to IBN maintained the microstructure of the cortical bone 
by reducing bone turnover as indicated by the maintenance 
of Ct.Ar, Ct.Wi, Ma.Ar, and Ec.Pm at the levels of the PTH 
group, and the decreases in endocortical OS/BS and MS/
BS as compared with the PTH group. These results sug-
gested that the maintenance of the biomechanical strength 
of the femoral shaft by switching to IBN can be attributed 
to IBN’s effects on cortical microstructure as well as on 
BMD.
The concern with PTH therapy in osteoporosis is that 
the use of PTH is limited to no more than 2 years and that 
treatment with anti-resorptive agents sequentially after 
withdrawal of PTH is required to maintain bone mass. 
Daily treatment with alendronate immediately after the dis-
continuation of PTH maintains or increases BMD of the 
lumbar spine and femoral neck in postmenopausal women 
with osteoporosis [9, 12]. Weekly treatment with zole-
dronate after PTH withdrawal also inhibits the decrease in 
bone mass in OVX rats [24]. IBN is administered monthly 
in Japan for the treatment of osteoporosis [14]. In the pre-
sent study, we administered IBN once every 4 weeks to 
OVX rats, and demonstrated that this long-interval dosing 
regimen of IBN could maintain bone mass and bone bio-
mechanical strength after PTH withdrawal. IBN maintained 
BMD, biomechanical strength, and microstructure not only 
of the trabecular bone but also of the cortical bone after 
PTH withdrawal. The affinity of bisphosphonates for bone 
mineral influences their distribution within bone, and it is 
suggested that bisphosphonates with a lower affinity for 
bone mineral can penetrate more deeply into cortical bone 
[25]. IBN has comparatively low mineral-binding affinity; 
therefore, this lower affinity may contribute to the benefi-
cial effect of IBN on cortical bone [26].
In addition to increasing cortical thickness or Ct.Ar, 
PTH treatment has also been reported to increase cortical 
porosity in monkeys as well as humans [27, 28]. However, 
in rats cortical porosity by intermittent administration of 
PTH is not observed due to the lack of intracortical remod-
eling, and in this study we found no cortical porosity after 
PTH administration in the femoral midshaft by histologi-
cal observation (data not shown). Since Iwamoto et al. have 
demonstrated that ibandronate decreased PTH-induced 
cortical porosity in the femoral diaphysis in rabbits [29], it 
is possible that when significant intracortical remodeling 
is present in animal models as it is in human, ibandronate 
may reduce cortical porosity induced by PTH.
In summary, we investigated the effects of intermit-
tent IBN treatment after withdrawal of PTH in OVX rats. 
IBN suppressed bone turnover and maintained BMD, 
biomechanical strength, and bone microstructure in the tra-
becular bone of the lumbar spine and in the cortical bone of 
the femur. It is expected that these results will be confirmed 
in patients with osteoporosis treated with IBN after with-
drawal of PTH.
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